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Thrombosis Resulting from Heparin Therapy 
Lisa L. Gottschling, Pharm.D., and Cesar Alaniz, Pharm.D. 
Heparin is widely used in current practice for a variety of indications. It is 
well known that it can cause thrombocytopenia, but not that thrombosis may 
also develop in thrombocytopenic patients and cause significant morbidity 
and  mortality. A 56-year-old woman developed heparin-induced 
thrombocytopenia with thrombosis that resulted in the amputation of her leg. 
It  is proposed that the reaction has an immune-mediated mechanism. Several 
ways of diagnosing the condition are available, specifically the serotonin- 
release assay and an enzyme-linked immunosorbent assay. The investigational 
agent danaproid may be effective in the treatment of heparin-induced 
thrombocytopenia with thrombosis. 
(Pharmacotherapy 1996; 16( 3):469-472) 
Thrombocytopenia is a well-known adverse 
effect of heparin administration. Current 
estimates of frequency lie between 5% and 10% 
of patients who receive heparin. 1-3 Thrombo- 
cytopenia itself may not present great danger, but 
these patients are at risk of developing a little- 
recognized and very dangerous adverse effect of 
heparin. Although it is rare (10-20% of those 
with thrombocytopenia) ,’ platelet thrombi, or so- 
called white clots, may form in large arteries and 
veins of these patients. When untreated,  
significant morbidity and mortality can result, as 
high as 60% and 30%, respectively4-’ A patient 
developed thrombotic complications while 
receiving heparin. She was eventually managed 
with the investigational agent danaproid (Orgaran, 
ORG-10172; Organon, West Orange, NJ). 
Case Report 
A 56-year-old woman was seen in  the 
emergency department on transfer from her local 
hospital with a diagnosis of thrombocytopenia 
and disseminated intravascular coagulation 
(DIC). She was admitted to the local hospital 14 
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days earlier complaining of substernal chest pain 
with radiation to her left jaw, neck, and arm. 
Treatment began with intravenous heparin and 
nitroglycerin. She was eventually diagnosed as 
having had a subendocardial myocardial infarc- 
tion, with a peak creatine kinase of 442 UL. 
One week after admission cardiac catheteri- 
zation through the right femoral artery confirmed 
coronary artery disease. Shortly after this 
procedure the woman developed ischemia in her 
left leg secondary to emboli. She immedi-ately 
underwent a left femoral embolectomy, left 
pop li t eal t hr  o mb o em b o 1 e c t o my, and patch 
angioplasty of her left femoral artery. 
Three days later an aortofemoral angiogram 
revealed acute thrombosis of the superficial 
femoral artery at  the level of adduction. 
Urokinase thrombolytic therapy was attempted, 
but failed to relieve the ischemia, and gangrene 
began to develop. She underwent a left femoral- 
popliteal bypass with a saphenous vein graft. 
Despite these efforts, her left leg continued to 
deteriorate, and 12 days after admission the 
patient underwent an above-the-knee amputation. 
During the course of these events the woman 
developed thrombocytopenia and signs of DIC 
despite the discontinuation of heparin.  
Progressive swelling of the right arm was noted 
for 1-2 days after surgery, and 14 days after her 
admission she was transferred to our hospital for 
further management. 
On transfer she complained of excruciating left 
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stump pain that required a patient-controlled 
morphine pump and around-the-clock meperidine. 
Her platelet count was reported from the other 
hospital as 36,000/~1. Heparin was strictly avoided 
and the woman was managed supportively. 
Over the next 2 days her platelet count began 
to rise to 44,000/~1 and 76,0OO/pl. Coagulation 
tests were' performed (Table 11, and a method 
for anticoagulation was pursued. The diagnosis 
of heparin-induced thrombocytopenia with 
thrombosis (HITT) was made after a positive 
heparin-induced 14C-serotonin platelet-release 
test. On the second day of hospitalization a 
Greenfield filter was placed and intravenous 
dextran 25 mVhour was started. 
Treatment with danaproid began 3 days after 
transfer on a compassionate use protocol 
(platelet count 73,OOO/pl). The patient was 
given a 2500-U bolus loading dose of danaproid 
followed by a continuous infusion of 400 Uhour, 
a t  which point intravenous dextran was 
discontinued. Warfarin therapy was instituted on 
day 7 and the patient's international normalized 
ratio was stabilized over 4 days. On hospital day 
10 danaproid was discontinued and the woman 
was maintained with warfarin. Her platelets had 
completely recovered at this time and were 
329,OOO/pl. The patient was discharged to 
rehabilitation on hospital day 21. 
Discussion 
Heparin-induced thrombocytopenia with 
thrombosis generally occurs 4-15 days after 
treatment is begun, although it may take less 
time if a patient has had exposure to the drug 
(1-9 days).'.4-5.8,9 The effect is not dose or route 
related (intravenous or subcutaneous) ,l ,  4, 6 ,  lo and 
although some studies report a higher frequency 
with bovine heparin, it is thought that frequency 
is similar with both bovine and porcine sources 
of the drug. ', 4, 
The mechanism of HITT is not completely 
understood, but it is thought to be the result of a 
complex immunologic response.', 3-6, ', 11-14 Th' 1s 
is in  contrast  to mild,  transient thrombo- 
cytopenia due to heparin (>100,000 platelets), 
which is thought to be caused by a proaggregant 
effect of the drug on  platelets, leading to 
sequestration by the spleen and reticuloen- 
dothelial system.3, 5, 12, l3 This reaction does not 
result in thrombosis and usually reverses even 
while drug administration  continue^.^. l3  In HITT, 
heparin binds to circulating platelet factor 4 
(PF4) that has been released from activated 
Table 1. Coagulation Values Measured During the First 
Days of Admission 
Test Result Reference 
Antithrombin 111 activity (mg/dl) 90 
Fibrinogen (mg/dl) 270 
Fibrin split product (mg/ml) 32 
Protein C activity (%) 103 
Protein C antigen (%) 71 
Protein S antigen (%) 62 
Dilute Russell viper venom time ratio 










14c-serotonin release test (U/ml) 0.1 ; :L; 1 positive 
100 
platelets, and these macromolecular complexes 
are thought to be the major 11, l 5  
Antibodies directed against these complexes may 
then bind to platelet Fc receptors, resulting in 
fixation of complement that leads to platelet 
activation, release of a-granule contents (PF4, 
thromboxane Bl, serotonin, Ietc.) and aggregation, 
which repeats the cycle.3, 6 ,  8, ''2 12, 15, l6 It is also 
believed that endothelial-bound PF4 is an 
additional target for PF4-heparin antibodies, 
either IgG or IgM, that can lead to injury and a site 
for the formation of thrombosis.16 
One study attempted to identify clinical or 
laboratory risk factors that may help predict 
which patients with heparin-induced thrombo- 
cytopenia are likely to develop thrombosis." 
Laboratory indexes studied included antithrombin 
111, heparin cofactor 11, protein C, and factor X, 
which are all coagulation inhibitors. The authors 
reported similar decreases in  all patients 
regardless of isolated thrombocytopenia or 
thrombocytopenia with thrombosis. 
The indication for heparin treatment provided 
information for determining clinical risk factors 
in the study population. The risk of arterial 
thrombosis increased (p<O.OOl) in  patients 
receiving heparin for a cardiovascular indication 
(myocardial infarction, cardiac surgery). In 
addition, antecedent surgery (p<O.OO 1) appeared 
to be a risk factor for venous thrombosis. 
Malignancy, sepsis, and concurrent drug use did 
not correlate with thrombosis. l7 Factors proposed 
by other authors as risks for development of 
thrombosis include atherosclerosis or vascular 
injury due  to surgery, venous stasis, and 
increased numbers of platelet Fc receptors.12 
Until recently, the diagnosis of HITT relied on 
clinical features and platelet aggregation assays. 
The latter are of limited value because of 
variability in methods, as well as low sensitivity 
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and ~pecificity.~. 15, lR Routine coagulation tests 
may help to distinguish HITT from other clotting 
disorders, but still cannot definitively diagnose 
the condition. For example, in contrast to DIC, 
fibrinogen levels and prothrombin time are 
usually normal in HITT, and fibrin split products 
are normal or slightly elevated.’ 
Currently, however, two assays are available 
that diagnose the reaction with greater specificity 
and attribute it to heparin use. The first test is 
performed by measuring heparin-induced platelet 
serotonin release. A control blood sample is 
obtained from a patient who is taking no drugs, 
and the platelets in this sample are labeled with 
“C-serotonin. The serum from a heparin-treated, 
thrombocytopenic patient is added to the labeled 
platelet-rich serum and heparin is mixed into the 
vial in various concentrations. After a standard 
length of time the reaction is quenched, the 
sample is centrifuged, and the radioactivity of the 
supernatant is measured.2 
The specificity of this test is based on the 
observation that patients who have a definite 
clinical diagnosis of HITT have a specific 
aggregation test result: at therapeutic concen- 
trations, heparin induces platelet aggregation; at  
high concentrations, platelet aggregation is 
inhibited due to the fact that  the high 
concentrations disrupt heparin-PF4 complexes 
and inhibit binding of the antibody.’. l1 Release of 
“C-serotonin is a more specific marker of platelet 
activation than is a platelet-aggregation test.2 A 
“C-serotonin test is considered positive when 
more than 20% of total radioactivity is measured 
with 0.1 U/ml of heparin and less than 20% is 
measured with 100 U/ml of 
The immune nature of HITT means that it can 
also be detected by an  enzyme-linked 
immunosorbent assay (ELISA). An ELISA is 
designed to detect the presence of antibodies 
directed against PF4-heparin complexes by 
coating a plate with the antigen itself. It appears 
from several studies that this is more specific and 
sensitive than 14C-serotonin release in detecting 
lower concentrations of antibodie~.~. l6 Another 
possible advantage of the ELISA is that it can 
detect IgG, IgA, and IgM antibodies. The “C- 
serotonin-release test can detect only IgG 
antibodies because i t  depends on platelet 
activation by specific Fc receptors (FcRII).15 A 
disadvantage is that it cannot detect cross- 
reactivity like the heparin-induced platelet 
activation (HIPA) test’* and it will not diagnose 
the condition if the reaction is the result of an 
antigen other than PF4-heparin c~mplexes.~.  l1 
l7 
The challenge with a patient who has 
developed HITT is how to continue anticoagu- 
lation if heparin must be discontinued. A 
number of different methods have been described 
in the literature, including the administration of 
aspirin, dipyridamole, low molecular weight 
heparins (LMWHs), intravenous dextran, and 
plasmapheresis. In our patient the investigational 
drug danaproid, a heparinoid, was obtained on a 
compassionate use basis. Danaproid is composed 
of low molecular weight glycosaminoglycuronans 
including heparan sulfate 84%, dermatan sulfate 
12%, and chondroitin sulfate 4%. Its ratio of 
anti-Xa activity to anti-IIa activity is about 28 
times greater than that of heparin1* and it has 
essentially no effect on platelets.” This agent has 
even demonstrated inhibition of antibody- 
induced platelet aggregation and release of 
thromboxane B2.’” ” 
A study of danaproid a s  an alternative 
anticoagulant in cases of HITT reported positive 
 result^.'^ Of the 230 patients with heparin- 
induced thrombocytopenia, 159 also had at least 
one thrombotic complication. In 88 of these 
patients the complications were due to an  
immune reaction to heparin administration. The 
study showed that 194 (92.8%) of 209 patients 
were adequately treated with danaproid. Seven 
patients died probably or possibly due to the 
drug; causes were bleeding in  one patient, 
thrombosis in five, and septic shock in one. 
Other bleeding events occurred in 40 patients, 14 
serious, 26 minor. 
In the same study, the cross-reactivity of 
danaproid with the heparin-induced antibody 
was compared with that of selected LMWHs 
(fraxiparine, fragmin, clexane [ enoxaparin] ). 
When a plasma sample tested positive for the 
heparin-induced antibody, an aggregation test 
was performed with danaproid and the LMWHs 
as well. Cross-reactivity for danaproid was less 
than 10% compared with greater than 90% for 
the LMWHs.19 Cross-reactivity also was 
addressed by a number of other studies using a 
variety of methods. Again, in each of them the 
cross-reactivity of LMWHs with heparin ranged 
from 78-94% and that of danaproid ranged from 
10-18°h.20~2’ 
A higher concentration of the LMWHs than 
heparin is necessary to produce the reaction 
because it is a t  this higher concentration that 
optimum binding to PF4 takes place. The 
concentration appears to be inversely propor- 
tional to the molecular weight of the drug.3 
Another factor that may affect cross-reactivity is 
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the drug’s degree or grade of sulfation.22 One 
group studied the individual components of 
danaproid and found that dermatan sulfate and 
heparan sulfate have a low capacity for binding 
the PF4-heparin antibody3 
Clinical Application and Conclusion 
Heparin-induced thrombocytopenia with 
thrombosis is not frequently encountered by 
practitioners, nor is it routinely considered in the 
differential diagnosis of spontaneous thrombi 
formation. Because it is very serious, however, 
medical staff must be alert to the possibility of a 
heparin reaction and monitor patients closely. A 
complete drug history from the patient is 
necessary. If an agent has caused HITT in the 
past, any form of rechallenge, regardless of length 
of treatment, can be fatal.Ig Platelet counts 
should be measured regularly, because early 
detection of this disorder is critical; monitoring 
daily or every other day is recommended.’, l4 
Appropriate action must  be taken when a 
decreased platelet count is reported to prevent 
any deterioration in status. 
Patients who develop thrombocytopenia 
should be examined for clinical signs of emboli 
such as pain and swelling in the extremities. If 
such symptoms are noted, heparin should be 
discontinued immediately and other anticoagu- 
lant therapy be instituted. A platelet aggregation 
or activation test should be performed to confirm 
the source of thrombocytopenia, preferably the 
heparin-induced serotonin-release test or PF4- 
heparin ELISA. 
It has been suggested that an in vitro cross- 
reactivity test also be performed if the alternative 
agent is a glycosaminoglycan (enoxaparin or 
other LMWH, danaproid). If this result is 
negative, alternative therapy may continue while 
the clinical manifestations of thrombosis are 
monitored for improvement. Despite a negative 
cross-reactivity test result, an in vivo reaction 
cannot be ruled out  because of low test 
sensitivity, especially in  patients who are 
currently thrombocytopenic. If the test is 
positive, i t  is imperative that the patient be 
immediately converted to an agent that is not 
cross-reactive, or be given oral anticoagulant 
therapy, if possible. l9 Although many recent 
advances have been made in the diagnosis and 
treatment of HITT, clinicians must continually be 
aware of the syndrome and its consequences. 
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